Key Highlights
• Fennec Pharmaceuticals reported Q2 2026 net product sales of $17.1 million, up approximately 78 percent year-over-year, beating the $16.2 million estimate by 0.95 percent.
• The company recorded record non-GAAP adjusted EBITDA of approximately $2.8 million, compared to a loss of $1.2 million a year ago.
• Commercial momentum accelerated into the third quarter, with July marking an all-time high for completed PEDMARK infusions, new patient enrollments, active patients on therapy, and new customers.
• Medical affairs expansion drove a 63 percent increase in unique healthcare provider reach and a 72 percent increase in affiliated sites reached in the second quarter.
Seventh Consecutive Quarter of Growth Driven by Expanding Adoption
Fennec Pharmaceuticals Inc. (NASDAQ:FENC) reported second quarter net product sales of $17.1 million, up from $9.7 million a year ago, marking the company's seventh consecutive quarter of sales growth. Fennec is a specialty pharmaceutical company focused on the development and commercialization of PEDMARK, a first-in-class treatment designed to reduce the risk of hearing loss caused by cisplatin chemotherapy in pediatric and young adult cancer patients. The company recorded record non-GAAP adjusted EBITDA of approximately $2.8 million, compared to a loss of $1.2 million in the prior-year period, with Earnings Per Share of $0.05 versus a loss of $0.11 a year earlier.
Management said sales calls increased 280 percent in the second quarter and Demand grew double digits over the first quarter, driven largely through the company's finisher patient services hub and inpatient infusion channel, which together represent over half of the company's business. Total cash Operating Expense guidance for 2026 remains at approximately $50 million, with 20 to 22 million dollars, or about 40 percent, expected in the second half of the year, and cash and cash equivalents stood at $41.2 million as of June 30, 2026.
July Marks All-Time High Across Key Commercial Metrics
Commercial momentum accelerated into the third quarter, with management reporting that July marked an all-time high for completed PEDMARK infusions, new patient enrollments, active patients on therapy, and new customers. Medical affairs expansion contributed meaningfully to this trend, driving a 63 percent increase in unique healthcare provider reach and a 72 percent increase in affiliated sites reached during the second quarter, which management believes is translating directly into broader adoption of the treatment among oncology centers treating pediatric and young adult cancer patients.
The company added a third investigator-sponsored study during the quarter, in collaboration with the University of Arizona Cancer Center, alongside ongoing investigator-sponsored studies with Tampa General Hospital and City of Hope, and a Japan-based investigator-sponsored study that was selected for oral presentation at a September 2026 medical meeting. Management said these studies help build broader clinical evidence and awareness of PEDMARK's benefits beyond the initial approved indications, though the company noted the specific Revenue contribution and timeline from expanded clinical adoption resulting from these studies remains difficult to quantify at this stage.
Disease Awareness Campaign and Guidance Considerations for 2027
Fennec launched a disease awareness campaign called In These Nuts at the Indianapolis 500 and the American Society of Clinical Oncology meeting to raise awareness of cisplatin-induced hearing loss and PEDMARK as a treatment option, which management said generated strong engagement metrics among both clinicians and caregivers. The company said it does not currently provide formal revenue guidance for 2026 but is considering providing guidance for 2027, alongside evaluating potential Japan and Asia-Pacific Partnership and licensing opportunities for PEDMARK to expand the product's international reach.
Management did not commit to a specific timeline for when a Japan or Asia-Pacific partnership might be finalized, characterizing these discussions as ongoing rather than imminent, which leaves some uncertainty around the pace and scale of international expansion relative to the company's continued strength in the U.S. market.
Conclusion
Fennec Pharmaceuticals delivered its seventh consecutive quarter of sales growth, with record profitability metrics and commercial momentum that accelerated further into July, reflecting deepening adoption of PEDMARK across expanding healthcare provider networks. The company's decision to consider formal revenue guidance for 2027 rather than the current year suggests management wants additional visibility into the durability of recent growth trends before committing to specific targets. Continued expansion of medical affairs reach, the maturation of ongoing investigator-sponsored studies, and the eventual outcome of potential Japan and Asia-Pacific partnership discussions are likely to shape the trajectory of PEDMARK adoption into 2027.
_11_19_2026_19_19_13_574021.jpg)





Please wait processing your request...